Friday, January 22, 2021

Latest Posts

Atalanta Therapeutics: Raises $110M in Series A Funding

  • Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
  • The financing was provided exclusively by F-Prime Capital
  • Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group
  • As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets
  • The company will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products
  • The strategic collaboration with Genentech involves the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases

Latest Posts

Don't Miss